{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:14:15Z","timestamp":1792113255128,"version":"4.4.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,26]]},"abstract":"<jats:p>Sacubitril\/valsartan is an angiotensin receptor neprilysin inhibitor (ARNI) that has been shown in multiple clinical trials to have clinical benefits and is recommended by major clinical management guidelines as a first-line treatment for heart failure with reduced ejection fraction (HFrEF). The most significant benefit that was observed in clinical trials is its effect in reducing hospital readmissions. However, little evidence supports its effectiveness in practice, especially in Saudi Arabia. A multicenter retrospective cohort study was conducted using the patient medical records at 2 tertiary hospitals in Saudi Arabia. Eligible patients were adults (\u226518 years old) with a confirmed diagnosis of HFrEF who were discharged on either sacubitril\/valsartan or angiotensin-converting enzyme inhibitors (ACEI)\/angiotensin receptor blockers (ARB) in addition to the other recommended therapy for HFrEF. The primary endpoint was the all-cause 30-day readmission rate. The secondary endpoints included all-cause readmissions at 60-day, 90-day, and 12 months. Additionally, 30-day, 60-day, and 90-day readmissions due to HF were evaluated. A total of 398 patients were included in our analysis; 199 (50.0%) received sacubitril\/valsartan (group 1), and 199 (50.0%) received ACEI\/ARB (group 2). Our results showed that all-cause 30-day readmissions in group 1 were significantly lower than in group 2 (7% vs 25.0%, RR 0.28, 95% Cl 0.16\u20130.49; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). Additionally, the secondary outcomes showed significantly fewer 60-day, 90-day, and 12-month all-cause readmissions were identified in group 1 compared to group 2 (11% vs 30.7%, RR 0.36, 95% CI 0.23\u20130.56; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001), (11.6%. vs 32.6%, RR 0.35, 95% CI 0.23\u20130.55; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001) and (23.6% vs 51.2%, RR 0.46, 95% CI 0.35\u20130.62; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001), respectively. Furthermore, HF readmissions at 30-day, 60-day, and 90-day in group 1 were significantly lower than in group 2 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). Sacubitril\/valsartan for the treatment of HFrEF is associated with a significantly lower rate of all-cause readmission as well as HF readmissions compared to ACEI\/ARB. These benefits extend up to 12 months post-discharge.<\/jats:p>","DOI":"10.1097\/md.0000000000038960","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T14:14:56Z","timestamp":1722003296000},"page":"e38960","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effect of sacubitril\/valsartan on hospital readmissions in heart failure with reduced ejection fraction in Saudi Arabia: A multicenter retrospective cohort study"],"prefix":"10.1097","volume":"103","author":[{"given":"Samiah","family":"Alsohimi","sequence":"first","affiliation":[{"name":"King Abdulaziz University Hospital, Jeddah Saudi Arabia"},{"name":"King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Almagthali","sequence":"additional","affiliation":[{"name":"King Abdulaziz University Hospital, Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Mandar","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatmah","family":"Ghandourah","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"AlButi","sequence":"additional","affiliation":[{"name":"King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah","family":"Alshehri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aljabri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia"},{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3997-676X","authenticated-orcid":false,"given":"Mohannad","family":"Alshibani","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250716","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.mpmed.2018.07.004","article-title":"Heart failure: classification and pathophysiology.","volume":"46","author":"Brahmbhatt","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R2-20250716","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","article-title":"Acute heart failure.","volume":"6","author":"Arrigo","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20250716","doi-asserted-by":"crossref","first-page":"263","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure.","volume":"11","author":"Schwinger","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"R4-20250716","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5539\/gjhs.v8n3p49","article-title":"Quality of life for Saudi patients with heart failure: a cross-sectional correlational study.","volume":"8","author":"AbuRuz","year":"2016","journal-title":"Glob J Health Sci"},{"key":"R5-20250716","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2753.2011.01773.x","article-title":"A meta-analysis of hospital 30-day avoidable readmission rates.","volume":"18","author":"van Walraven","year":"2012","journal-title":"J Eval Clin Pract"},{"key":"R6-20250716","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines.","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R7-20250716","doi-asserted-by":"crossref","first-page":"e799","DOI":"10.1097\/MJT.0000000000000065","article-title":"Effective strategies in reducing rehospitalizations in patients with heart failure.","volume":"23","author":"Al-Khazaali","year":"2016","journal-title":"Am J Ther"},{"key":"R8-20250716","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2018.09.039","article-title":"Early readmission for heart failure: an avoidable or ineluctable debacle?","volume":"277","author":"Palazzuoli","year":"2019","journal-title":"Int J Cardiol"},{"key":"R9-20250716","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/chf.12031","article-title":"Decreased readmissions and improved quality of care with the use of an inexpensive checklist in heart failure.","volume":"19","author":"Basoor","year":"2013","journal-title":"Congest Heart Fail"},{"key":"R10-20250716","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/ejhf.2163","article-title":"Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study.","volume":"23","author":"Bhatt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R11-20250716","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/jamacardio.2020.3757","article-title":"Remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.","volume":"5","author":"Desai","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R12-20250716","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/ejhf.2378","article-title":"Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction.","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R13-20250716","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R14-20250716","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"R15-20250716","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure.","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"R16-20250716","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ahj.2017.12.021","article-title":"Rationale and methods of the prospective study of biomarkers, symptom improvement, and ventricular remodeling during sacubitril\/valsartan therapy for heart failure (PROVE-HF).","volume":"199","author":"Januzzi","year":"2018","journal-title":"Am Heart J"},{"key":"R17-20250716","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"R18-20250716","doi-asserted-by":"crossref","first-page":"110596","DOI":"10.1016\/j.biopha.2020.110596","article-title":"The role of sacubitril\/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: from clinical trials to real-world settings.","volume":"130","author":"Mazza","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R19-20250716","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCOUTCOMES.108.802686","article-title":"An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure.","volume":"1","author":"Keenan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R20-20250716","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/IJGM.S150676","article-title":"Determining 30-day readmission risk for heart failure patients: the Readmission After Heart Failure scale.","volume":"11","author":"Chamberlain","year":"2018","journal-title":"Int J Gen Med"},{"key":"R21-20250716","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.acvd.2020.03.018","article-title":"Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology.","volume":"113","author":"Mewton","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"R22-20250716","first-page":"876","article-title":"Sacubitril\/valsartan adherence and postdischarge outcomes among patients hospitalized for heart failure with reduced ejection fraction.","volume":"9","author":"Carnicelli","year":"2021","journal-title":"Heart Failure"},{"key":"R23-20250716","doi-asserted-by":"crossref","first-page":"e021459","DOI":"10.1161\/JAHA.121.021459","article-title":"Clinical effectiveness of sacubitril\/valsartan among patients hospitalized for heart failure with reduced ejection fraction.","volume":"10","author":"Greene","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"R24-20250716","doi-asserted-by":"crossref","first-page":"101149","DOI":"10.1016\/j.eclinm.2021.101149","article-title":"Clinical outcomes of Sacubitril\/Valsartan in patients with acute heart failure: a multi-institution study.","volume":"41","author":"Chen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R25-20250716","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation.","volume":"74","author":"Chang","year":"2019","journal-title":"J Cardiol"},{"key":"R26-20250716","doi-asserted-by":"crossref","first-page":"W-163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.","volume":"147","author":"Vandenbroucke","year":"2007","journal-title":"Ann Intern Med"},{"key":"R27-20250716","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4097\/kjae.2017.70.4.407","article-title":"Statistical data preparation: management of missing values and outliers.","volume":"70","author":"Kwak","year":"2017","journal-title":"Korean J Anesthesiol"},{"key":"R29-20250716","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12910-019-0431-5","article-title":"Reporting of ethical approval and informed consent in clinical research published in leading nursing journals: a retrospective observational study.","volume":"20","author":"Wu","year":"2019","journal-title":"BMC Med Ethics"},{"key":"R30-20250716","first-page":"e2022319","article-title":"Retrospective observational studies: Lights and shadows for medical writers.","volume":"93","author":"De Sanctis","year":"2022","journal-title":"Acta Biomed"},{"key":"R31-20250716","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40119-021-00252-4","article-title":"Hospitalization rates in patients with heart failure and reduced ejection fraction initiating sacubitril\/valsartan or angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers: a retrospective cohort study.","volume":"11","author":"Houchen","year":"2022","journal-title":"Cardiol Ther"},{"key":"R32-20250716","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.cardfail.2022.02.011","article-title":"Medical therapy during hospitalization for heart failure with reduced ejection fraction: the VICTORIA registry.","volume":"28","author":"Greene","year":"2022","journal-title":"J Card Fail"},{"key":"R33-20250716","doi-asserted-by":"crossref","first-page":"e011089","DOI":"10.1161\/JAHA.118.011089","article-title":"Lower hospitalization and healthcare costs with sacubitril\/valsartan versus angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker in a retrospective analysis of patients with heart failure.","volume":"8","author":"Albert","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R34-20250716","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamacardio.2020.2822","article-title":"Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction.","volume":"5","author":"Gaziano","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R35-20250716","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchf.2019.08.003","article-title":"Comparative effectiveness of sacubitril-valsartan versus ACE\/ARB therapy in heart failure with reduced ejection fraction.","volume":"8","author":"Tan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R36-20250716","doi-asserted-by":"crossref","first-page":"E470","DOI":"10.1532\/hsf.3029","article-title":"The impact of discharged loop diuretic dose to home dose on hospital readmissions in patients with acute decompensated heart failure: a retrospective cohort study.","volume":"23","author":"Alshibani","year":"2020","journal-title":"Heart Surg Forum"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T23:00:25Z","timestamp":1752706825000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":35,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038960","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}